Carbylan Therapeutics (NASDAQ:CBYL): The mean short term price target for Carbylan Therapeutics (NASDAQ:CBYL) has been established at $5.38 per share. The higher price target estimate is at $10 and the lower price target estimate is expected at $1 according to 2 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $6.53
Many analysts have stated their opinion on the company shares. Brokerage firm JMP Securities downgrades its rating on Carbylan Therapeutics (NASDAQ:CBYL). The shares have been rated Market Perform. Previously, the analysts had a Market Outperform rating on the shares. The rating by the firm was issued on April 18, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities,The director officer (President & CEO) of Carbylan Therapeutics, Inc., Renzi David sold 10,000 shares at $3.7 on December 30, 2015. The Insider selling transaction had a total value worth of $37,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Carbylan Therapeutics (NASDAQ:CBYL) : On Monday heightened volatility was witnessed in Carbylan Therapeutics (NASDAQ:CBYL) which led to swings in the share price. The stock opened for trading at $1.12 and hit $1.24 on the upside , eventually ending the session at $1.23, with a gain of 8.85% or 0.1 points. The heightened volatility saw the trading volume jump to 1,359,791 shares. The 52-week high of the share price is $8.88 and the company has a market cap of $32 million. The 52-week low of the share price is at $0.52 .
Carbylan Therapeutics, Inc. (Carbylan Therapeutics) is a clinical-stage specialty pharmaceutical company. The Company is focused on the development and commercialization of combination therapies that address unmet medical needs. The Companys focus is on the development of Hydros-TA, an intra-articular (IA), injectable product candidate to treat pain associated with osteoarthritis (OA), of the knee. Hydros-TA utilizes cross-linking technology to deliver both rapid pain relief with a low dose corticosteroid triamcinolone acetonide, (TA), and sustained pain relief from hyaluronic acid viscosupplement. It is comprised of bacterially-derived HA-based hydrogel particles suspended in a solution of hyaluronic acid. Hydros-TA is being studied in its COR1.1 trial, a Phase III, multi-center, randomized, double-blind, three-arm trial with grade two and grade three OA of the knee.